We dichotomized CDKN2A intact meningiomas into CDKN2Ahigh and CDKN2Alow cases by selecting an unbiased cut-off that was agnostic to outcome and was reproducible in each cohort that used different RNAseq techniques. This evidence concerns the gene CDKN2A and meningioma.